These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7917532)

  • 1. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study.
    Taube T; Kylmälä T; Lamberg-Allardt C; Tammela TL; Elomaa I
    Eur J Cancer; 1994; 30A(6):751-8. PubMed ID: 7917532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group.
    Kylmälä T; Tammela T; Risteli L; Risteli J; Taube T; Elomaa I
    Eur J Cancer; 1993; 29A(6):821-5. PubMed ID: 7683480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer.
    Elomaa I; Kylmälä T; Tammela T; Viitanen J; Ottelin J; Ruutu M; Jauhiainen K; Ala-Opas M; Roos L; Seppänen J
    Int Urol Nephrol; 1992; 24(2):159-66. PubMed ID: 1385586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.
    Kylmälä T; Taube T; Tammela TL; Risteli L; Risteli J; Elomaa I
    Br J Cancer; 1997; 76(7):939-42. PubMed ID: 9328156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal response to clodronate in prostate cancer with bone metastases.
    Fernández-Conde M; Alcover J; Aaron JE; Ordi J; Carretero P
    Am J Clin Oncol; 1997 Oct; 20(5):471-6. PubMed ID: 9345330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study.
    Taube T; Elomaa I; Blomqvist C; Beneton MN; Kanis JA
    Eur J Cancer; 1993; 29A(12):1677-81. PubMed ID: 8398293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates in prostate carcinoma.
    Adami S
    Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
    Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
    Dearnaley DP; Sydes MR; Mason MD; Stott M; Powell CS; Robinson AC; Thompson PM; Moffat LE; Naylor SL; Parmar MK;
    J Natl Cancer Inst; 2003 Sep; 95(17):1300-11. PubMed ID: 12953084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.
    O'Rourke N; McCloskey E; Houghton F; Huss H; Kanis JA
    J Clin Oncol; 1995 Apr; 13(4):929-34. PubMed ID: 7707121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain.
    Magnusson P; Larsson L; Englund G; Larsson B; Strang P; Selin-Sjögren L
    Clin Chem; 1998 Aug; 44(8 Pt 1):1621-8. PubMed ID: 9702948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer.
    Kylmälä T; Castrén-Kortekangas P; Seppänen J; Ylitalo P; Tammela TL
    Pharmacol Toxicol; 1996 Sep; 79(3):157-60. PubMed ID: 8884875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
    Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
    Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R
    J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL; Goa KL
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study.
    Rotstein S; Glas U; Eriksson M; Pfeiffer P; Hansen J; Söderqvist J; Bandmann U; Strid S
    Eur J Cancer; 1992; 28A(4-5):890-3. PubMed ID: 1388038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
    Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
    J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
    Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH
    Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostatic osteocondensing metastases and osteomalacia. Value of histomorphometric study. Preliminary results].
    Coindre JM; Mage P; Bui BN; Goussot JF; De Mascarel I; De Mascarel A; Trojani M
    Presse Med; 1985 Oct; 14(35):1823-7. PubMed ID: 2933667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer and bone metastases. The effect of clodronate.
    Kylmälä T
    Ann Chir Gynaecol; 1998; 87(1):59-60. PubMed ID: 9598233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.